Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical-stage biotech founded in 2014, advancing a pipeline centered on OT-101, a novel anti-TGF-β RNA therapeutic for cancers like diffuse intrinsic pontine glioma (DIPG) and viral infections including COVID-19. The company leverages a dual strategy of traditional drug development and a novel AI/DAO-driven platform (PDAOAI/Pet2DAO) to enhance research efficiency. With a focus on rare pediatric cancers and a partnership-driven, capital-efficient business model, Oncotelic aims to translate its RNA and small molecule candidates into treatments for significant unmet medical needs.

PDAOAI (AI-augmented literature intelligence for precision oncology) and Pet2DAO (AI/DAO/LLM-driven collaborative drug development platform). Core drug modality expertise in anti-TGF-β RNA therapeutics.

The anti-TGF-β space is competitive with several large biopharma and biotech companies developing monoclonal antibodies and other inhibitors. In DIPG and rare pediatric cancers, the landscape is less crowded but includes other investigational therapies, making clinical differentiation critical. The AI-for-drug-discovery sector is also highly competitive with numerous well-funded startups and tech giants.